Docoh
Loading...

AMRN Amarin

News

Pro users get this 30m faster
Cramer Weighs In On Paysafe, Xilinx And More
15 Apr 21
Small Cap, Media, Trading Ideas
On CNBC's "Mad Money Lightning Round," Jim Cramer said Keysight Technologies Inc (NYSE: KEYS) has been just red hot and he really likes it.
TENX: HELP Results & New Asset to Boot
14 Apr 21
Penny Stocks, Small Cap
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
50 Biggest Movers From Yesterday
14 Apr 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Tuesday's Intraday Session
13 Apr 21
Intraday Update, Markets, Movers
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
13 Apr 21
Biotech, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Amarin Commences Commercial Initiatives For VAZKEPA In European Union Following Recent Regulatory Approval For Cardiovascular Risk Reduction Indication
6 Apr 21
Biotech, General
Amarin Corporation plc (NASDAQ:AMRN) today provided updates regarding its plans for the commercial launch of VAZKEPA (icosapent ethyl) in Europe following the March 30, 2021 announcement of receipt of market
Looking Into Amarin Corp's Return On Capital Employed
30 Mar 21
Earnings, News
Amarin Corp (NASDAQ:AMRN) posted a 203.14% decrease in earnings from Q3. Sales, however, increased by 6.87% over the previous quarter to $167.25 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Amarin Corp is not utilizing their capital as effectively as possible.
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
30 Mar 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl
30 Mar 21
Biotech, News, Health Care, FDA, General
Amarin's Vascepa Recommended By Canadian Cardiovascular Society For Prevention Of Cardiovascular Diseases
29 Mar 21
Biotech, News, Health Care, FDA, General
HLS Therapeutics Inc announced the Canadian Cardiovascular Society had included ic
Amarin Highlights Inclusion Of Icosapent Ethyl In Multiple Journals
29 Mar 21
Biotech, General
Amarin Corporation plc (NASDAQ:AMRN) today announced that the Canadian Cardiovascular Society (CCS) and the Egyptian Heart Journal (EHJ) (the official journal of the Egyptian Cardiovascular Society) have
Amarin's Vascepa Associated With Stroke Reduction
17 Mar 21
Biotech, News, Health Care, FDA, General
Amarin Corporation plc (NASDAQ: AMRN) has
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
25 Feb 21
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Amarin Corp Q4 EPS $0.04 Beats $(0.01) Estimate, Sales $167.30M Beat $164.94M Estimate
25 Feb 21
Earnings, News
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent increase over earnings of $0.02 per share from the same
Earnings Scheduled For February 25, 2021
25 Feb 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings at $0.23 per share on revenue of $4.78 billion.
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
20 Feb 21
Biotech, Earnings, News, Penny Stocks, Previews, Small Cap, FDA, Trading Ideas
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Amarin Announces Its Corporate Partner In China, Edding, Has Progressed VASCEPQA Into Commencement Of The Regulatory Review Processes In Mainland China And Hong Kong
9 Feb 21
News, Global
Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA® (icosapent ethyl) into commencement of the regulatory review processes in Mainland China and
10 Health Care Stocks With Unusual Options Alerts In Today's Session
4 Feb 21
Health Care, Options, General
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
1 Feb 21
Health Care, Options, General
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of unusual options activity happening in the Health Care sector:
SVB Leerink Maintains Outperform on Amarin Corp, Raises Price Target to $16
1 Feb 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Ami Fadia maintains Amarin Corp (NASDAQ:AMRN) with a Outperform and raises the price target from $12 to $16.

Press releases

Pro users get this 30m faster
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
17 Apr 21
Press Releases
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and
Amarin Announces CEO Succession Plan
12 Apr 21
News, Management, Press Releases
John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 (GLOBE
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
6 Apr 21
Health Care, Press Releases, General
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
30 Mar 21
Health Care, Press Releases, General
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
29 Mar 21
Small Cap, Press Releases
CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on March 26, 2021 Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes and ≥1 cardiovascular
HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
17 Mar 21
Small Cap, Press Releases
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
17 Mar 21
News, Press Releases
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
25 Feb 21
Earnings, Press Releases
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA® in Europe and Continue to Advance Commercial Launch
Amarin to Present at Two Upcoming Investor Conferences
18 Feb 21
News, Press Releases
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
17 Feb 21
News, Press Releases
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®
16 Feb 21
Small Cap, Press Releases
Private payer health plan coverage in Canada for Vascepa is expected to reach more than 80% by the end of February 2021, up from 50% in November 2020 Coverage effective for statin-treated patients with elevated
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
29 Jan 21
Health Care, Press Releases, General
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
28 Jan 21
Small Cap, Press Releases
Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1  Chinese Society of Cardiology updated Guidelines now include Vascepa in its
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
25 Jan 21
Press Releases
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascular (CV) risk
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
21 Jan 21
Health Care, Press Releases
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated